2024/12/09
Shizuoka Cancer Center
The Shizuoka Cancer Center, Amjen, Inc., and MICIN, Inc. have launched on a collaborative project with “eConsent,” a brand-new system to obtain an informed consent through electronic tools, which enables to establish an on-line link between a hospital conducting a clinical trial and the other (i.e., partner hospital referring the patient.) The system is installed on “MiROHA,” a DCT (decentralized clinical trial) platform rendered by MICIN, who developed the system with an objective to promote DCT. This collaborative project is for a clinical trial initiated by Amjen and conducted at the Shizuoka Cancer Center. Clinical trials on MiROHA are supposed be subjected for untreated advancing cancers. Since biomarkers for such cancers have low expression frequencies, the clinical trials for them are expected to find small numbers of participants, as well as high exclusion rates at eligibility screenings. Therefore, in order to develop new effective cancer drugs and provide patients with new treatments promptly, it is a crucial issue to promote clinical trials through obtaining informed consents from as many potential participants as possible. With “eConsent,” a patient at a partner hospital can receive a thorough explanation on a clinical trial, and can remotely send his/her informed consent on-line upon agreeing on the participation. In other words, the patient at the partner hospital will be able to learn about the clinical trial without visiting the Shizuoka Cancer Center, and give his/her informed consent whenever he/she wishes to. This new system is expected to offer the chances to participate in clinical trials, for the patients who would have no information on clinical trials in other circumstances, or who could give up participating due to the distances from the Shizuoka Cancer Center otherwise.
